WASHINGTON, DC—Two-year results from the ABSORB III study presented today at the American College of Cardiology 2017 Scientific Session show that the Absorb GT1 bioresorbable vascular scaffold (BVS, ...
AMSTERDAM, NL — Consistent with prior trials, the risk of scaffold thrombosis was significantly higher in patients receiving the Absorb (Abbott Vascular) bioresorbable vascular scaffold (BVS) than an ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. WASHINGTON — At 2 years, the cumulative rate of target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results